Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
BioCryst Pharmaceuticals Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 4 distinct examiners and 4 distinct art units. SAEED, KAMAL A is the busiest examiner, with 1 pending action.
The one-to-one examiner and art-unit distribution indicates that each pending action follows its own examination path. Counsel should coordinate portfolio terminology and supporting disclosure without assuming that one response will address another matter. The SAEED assignment is a single active file, so the data supports focused matter management rather than examiner-specific escalation.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18894797 | HUMAN PLASMA KALLIKREIN INHIBITORS | SAEED, KAMAL A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268688 | DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS | HERNANDEZ, JACKSON J | 56d |
| 18647310 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | CORNET, JEAN P | — |
| 18286615 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | MAHLUM, JONATHAN DAVIS | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1628 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18894797 | HUMAN PLASMA KALLIKREIN INHIBITORS | SAEED, KAMAL A | 1626 | DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18647310 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | CORNET, JEAN P | 1628 | §103§112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18286615 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | — | Pending | Oct 12, 2023 |
| 18268688 | DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS | HERNANDEZ, JACKSON J | 1627 | §103Other | Final Rejection | 56d | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBioCryst Pharmaceuticals Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Kamal A Saeed has the most, with 1 of BioCryst Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
